John Dahldorf

Micro Medical Solutions (MMS), an innovative medical device company focused on improving outcomes for patients with Critical Limb Threatening Ischemia (CLTI), has appointed Vince Burgess and John Dahldorf to its Board of Directors. 

The appointments further strengthen MMS’s leadership as the company advances toward commercialization of its MicroStent™ technology. Burgess and Dahldorf join George Quinoy, Chairman of the Board and President & Chief Executive Officer, and Dr. Ron Solar, Board Member, bringing deep operational, financial, and medical device expertise to the organization.

John Dahldorf brings more than 25 years of experience leading finance and accounting functions for public and private healthcare companies. He currently serves as Chief Financial Officer of Q’Apel Medical, Inc. and as a Board Member of Hyperfine, Inc. Previously, he was CFO of Volcano Corporation, playing a key role in its acquisition by Royal Philips. Dahldorf holds a B.S. in Finance and an M.B.A. from Western Illinois University.

MMS’s MicroStent™, which has received FDA Breakthrough Device Designation, is currently under Premarket Approval review and is designed to improve blood flow, promote wound healing, and reduce amputations in patients with CLTI.